The Women’s Health Initiative (WHI) was a large, multi-center study involving approximately 68,000 women designed to evaluate ways to prevent chronic diseases in postmenopausal women.

One arm of the study included women aged 50–79 who were treated with a combination of conjugated equine estrogen (Premarin) and a synthetic progestin (Provera). After an average of 5.2 years, this portion of the trial was stopped early due to a modest increase in certain risks, including breast cancer, stroke, and cardiovascular events in that specific population.

Subsequent analysis has shown that these findings were influenced by several factors:

• Many participants were older (often in their 60s and 70s)
• Therapy was started many years after menopause
• The hormone formulations differ from those commonly used today

In another arm of the study, women who received estrogen alone did not show an increased risk of breast cancer and, in some analyses, had a lower incidence.

Today, we understand that hormone therapy should be individualized. For many women under age 60 or within 10 years of menopause, it can be a safe and effective treatment option when appropriately prescribed and monitored.

Menopausal symptoms may last a few months, several years, or longer. On average, symptoms last about 5 years, but this varies significantly.

The duration of therapy is individualized. Some patients use hormone therapy for a few years, while others may continue longer. Ongoing treatment decisions are made collaboratively between the patient and physician based on symptom relief, health status, and personal preferences.

Many women notice improvement in symptoms such as hot flashes and night sweats within days to weeks of starting therapy. For others, it may take several weeks to experience full benefit.

Some individuals may notice temporary side effects early on, including:

• Breast tenderness
• Bloating
• Headaches
• Vaginal spotting or bleeding

These symptoms are often mild and resolve as the body adjusts. If symptoms persist beyond a few weeks, adjustments to the dosage or formulation may be needed.

The relationship between hormone therapy and breast cancer is complex and depends on the type of hormones used, duration of use, and individual risk factors.

Research, including findings from the Women’s Health Initiative, shows that:

• Estrogen-only therapy has not been associated with an increased risk of breast cancer in certain populations
• Combined estrogen and synthetic progestin therapy (synthetic progesterone) may be associated with a small increased risk over time
• Some observational studies suggest that regimens using estradiol with micronized (natural) progesterone may have a more favourable risk profile, although ongoing research continues to refine our understanding.

A personalized assessment is essential when considering hormone therapy, particularly for individuals with additional risk factors.

Vaginal dryness is a common symptom of menopause caused by decreased estrogen levels, leading to thinning of the vaginal tissues.

Treatment options include:

• Local vaginal estrogen (such as estriol or estradiol creams, tablets, or rings) or local DHEA (prasterone)
• In some cases, additional therapies such as low-dose testosterone may be considered
• These treatments are typically very effective and have minimal systemic absorption.

Hormonal changes during menopause can contribute to weight changes. Hormone therapy itself is not a direct cause of significant weight gain.

Some individuals may experience temporary fluid retention with estrogen, while progesterone can have a mild diuretic effect. Achieving the right hormonal balance, along with attention to nutrition, sleep, and activity, helps minimize unwanted changes.

Hormone levels are typically monitored with periodic blood work, especially during the initial stages of treatment.

Follow-up is usually:

• Every 3–4 months initially until symptoms and levels are stable
• Then every 6–12 months for ongoing monitoring
• Regular screening such as mammograms, Pap tests, and pelvic imaging may also be recommended based on individual risk factors and age.

If you have a family physician, coordination of care and sharing of relevant test results helps ensure comprehensive management.

We provide individualized, evidence-informed care focused on improving quality of life while minimizing risk.

Treatment plans are tailored based on your symptoms, medical history, and preferences. When appropriate, bioidentical hormones may be used as part of a personalized approach, with careful monitoring and ongoing reassessment.

The best way to determine this is through a consultation. Together, we review your symptoms, health history, and goals to help you make an informed and confident decision about your care.

Still have questions?

We’re here to help. Book a consultation to discuss your symptoms and explore whether hormone therapy is right for you.